
Claims

1. ~~Compound~~ The use of a compound of the formula (I)



(I)

in which

R^1 represents hydrogen or (C_1-C_4)-alkyl,

R^2 represents hydrogen or (C_1-C_4)-alkyl,


where (C_1-C_4)-alkyl may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of fluorine, trifluoromethyl, trifluoromethoxy, (C_1-C_4)-alkoxy, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkoxy and (C_1-C_4)-alkylsulphonyl,

or

R^1 and R^2 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle which may contain a further heteroatom from the group consisting of N, O and S,

where the 4- to 7-membered heterocycle may be substituted by 1 to 2 substituents independently of one another selected from the group consisting of fluorine, trifluoromethyl, (C_1-C_4)-alkyl, trifluoromethoxy and (C_1-C_4)-alkoxy,

R^3 represents hydrogen or a group of the formula



where

\# represents the point of attachment to the oxygen atom,

R^4 represents hydrogen or the side group of a natural α-amino acid or its homologues or isomers,

R^5 represents hydrogen,

R^6 represents hydrogen,

R^7 represents hydrogen,

R^8 represents hydrogen or the side group of a natural α-amino acid or its homologues or isomers,

R^9 represents hydrogen,

R^{10} represents hydrogen or methyl,

R^{11} represents hydrogen or the side group of a natural α-amino acid or its homologues or isomers,

R^{12} represents hydrogen,

R^{13} represents hydrogen,

R^{14} represents hydrogen,

and the N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-oxides or salts thereof ~~for use in a method~~ in the manufacture of a medicament for the treatment and/or prevention of acute and/or chronic kidney disorders with or without concomittant acute and/or chronic heart disorders owing to renocardiac and/or cardiorenal syndrome.

2. ~~Compound~~ The use of a compound of the formula (I) according to Claim 1 in which

R^1 represents (C_1-C_4)-alkyl,

R^2 represents (C_1-C_4)-alkyl,

where (C_1-C_4)-alkyl may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of fluorine, trifluoromethyl, trifluoromethoxy, (C_1-C_4)-alkoxy, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkoxy and (C_1-C_4)-alkylsulphonyl,

or


R^1 and R^2 are each hydrogen

or


R^1 and R^2 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle which may contain a further heteroatom from the group consisting of N, O and S,

where the 4- to 7-membered heterocycle may be substituted by 1 to 2 substituents independently of one another selected from the group consisting of fluorine, trifluoromethyl, (C_1-C_4)-alkyl, trifluoromethoxy and (C_1-C_4)-alkoxy,

R^3 represents hydrogen or a group of the formula



or



where

represents the point of attachment to the oxygen atom,

R^4 represents hydrogen or the side group of a natural α-amino acid or its homologues or isomers,

R^5 represents hydrogen,

R^6 represents hydrogen,

R^7 represents hydrogen,

R^8 represents hydrogen or the side group of a natural α-amino acid or its homologues or isomers,

R^9 represents hydrogen,

R^{10} represents hydrogen or methyl,

R^{11} represents hydrogen or the side group of a natural α-amino acid or its homologues or isomers,

R^{12} represents hydrogen,

R^{13} represents hydrogen,

and the N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-oxides or salts thereof

in ~~a method~~ the manufacture of a medicament for the treatment and/or prevention of acute and/or chronic kidney disorders with or without concomittant acute and/or chronic heart disorders owing to renocardiac and/or cardiorenal syndrome.

3. ~~Compound~~ The use of a compound of the formula (I) according to Claim 1 in which

R^1 represents hydrogen or $(C_1$-$C_3)$-alkyl,


R^2 represents hydrogen or $(C_1$-$C_3)$-alkyl,

where $(C_1$-$C_3)$-alkyl may be substituted by 1 or 2 substituents independently of one another selected from the group consisting of fluorine, trifluoromethyl, methoxy, ethoxy, cyclopropyl and cyclobutyl,

R^1 and R^2 together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocycle which may contain a further heteroatom from the group consisting of N, O and S,

where the 4- to 6-membered heterocycle may be substituted by 1 to 2 substituents independently of one another selected from the group consisting of fluorine, trifluoromethyl, $(C_1$-$C_4)$-alkyl, trifluoromethoxy, methoxy and ethoxy,

R^3 represents hydrogen or a group of the formula



where

\# represents the point of attachment to the oxygen atom,

R^4 represents 3-aminopropan-1-yl,

R^5 represents hydrogen,

R^6 represents hydrogen,

R^7 represents hydrogen,

R^8 represents methyl,

R^9 represents hydrogen,

R^{10} represents hydrogen,

R^{11} represents methyl, 2-aminoeth-1-yl, 4-aminobut-1-yl, 3-guanidinopropan-1-yl or imidazol-4-ylmethyl,

R^{12} represents hydrogen,

R^{13} represents hydrogen,

R^{14} represents hydrogen,

and the N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-oxides or salts thereof ~~for use in a method~~ in the manufacture of a medicament for the treatment and/or prevention of acute and/or chronic kidney disorders with or without concomittant acute and/or chronic heart disorders owing to renocardiac and/or cardiorenal syndrome.

4. ~~Compound~~ The use of a compound of the formula (I) according to Claim 1 or 3 in which


R^1 represents hydrogen or ethyl,

R^2 represents hydrogen or ethyl,

or

R^1 and R^2 together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocycle which may contain a further heteroatom from the group consisting of N, O and S,

R^3 represents hydrogen or a group of the formula



where

represents the point of attachment to the oxygen atom,

R^4 represents 3-aminopropan-1-yl,

R^5 represents hydrogen,

R^6 represents hydrogen,

R^7 represents hydrogen,

R^8 represents methyl,

R^9 represents hydrogen,

R^{10} represents hydrogen,

R^{11} represents methyl, 2-aminoeth-1-yl, 4-aminobut-1-yl, 3-guanidinopropan-1-yl or imidazol-4-ylmethyl,

R^{12} represents hydrogen,

R^{13} represents hydrogen,

R^{14} represents hydrogen,

and the N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-oxides or salts thereof ~~for use in a method~~ in the manufacture of a medicament for the treatment and/or prevention of acute and/or chronic kidney disorders with or without concomittant acute and/or chronic heart disorders owing to renocardiac and/or cardiorenal syndrome.

5. ~~Compound~~ The use of a compound of the formula (I) according to one or more of Claims 1, 3 or 4 in which

R^1 represents hydrogen or ethyl,


R^2 represents hydrogen or ethyl,

or


R^1 and R^2 together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl or piperidinyl ring,

where the azetidinyl ring may be substituted by a methoxy substituent,

R^3 represents hydrogen or a group of the formula



or



where

represents the point of attachment to the oxygen atom,

R^4 represents 3-aminopropan-1-yl,

R^5 represents hydrogen,

R^6 represents hydrogen,

R^7 represents hydrogen,

R^8 represents methyl,

R^9 represents hydrogen,

R^{10} represents hydrogen,

R^{11} represents methyl, 2-aminoeth-1-yl, 4-aminobut-1-yl, 3-guanidinopropan-1-yl or imidazol-4-ylmethyl,

R^{12} represents hydrogen,

R^{13} represents hydrogen,

R^{14} represents hydrogen,

and the N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-oxides or salts thereof ~~for use in a method~~ in the manufacture of a medicament for the treatment and/or prevention of acute and/or chronic kidney disorders with or without concomittant acute and/or chronic heart disorders owing to renocardiac and/or cardiorenal syndrome.

6. ~~Compound~~ The use of a compound of the formula (I) according to one or more of Claims 1, 2, 3 or 4, selected from the group below:

2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulphanyl)-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile

2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulphanyl)-6-(diethylamino)-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile


2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulphanyl)-4-[4-(2-hydroxyethoxy)phenyl]-6-(3-methoxyazetidin-1-yl)pyridine-3,5-dicarbonitrile

2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulphanyl)-4-[4-(2-hydroxyethoxy)phenyl]-6-(pyrrolidin-1-yl)pyridine-3,5-dicarbonitrile

2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulphanyl)-4-[4-(2-hydroxyethoxy)phenyl]-6-(piperidin-1-yl)pyridine-3,5-dicarbonitrile,

and the N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-oxides or salts thereof ~~for use in a method~~ in the manufacture of a medicament for the treatment and/or prevention of acute and/or chronic kidney disorders with or without concomittant acute and/or chronic heart disorders owing to renocardiac and/or cardiorenal syndrome.

7. ~~Compound~~ The use of a compound of the formula



2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulphanyl)-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile

and the N-oxides, salts, solvates, salts of the N-oxides and solvates of the N-oxides or salts thereof ~~for use in a method~~ in the manufacture of a medicament for the treatment and/or prevention of acute and/or chronic kidney disorders with or without concomittant acute and/or chronic heart disorders owing to renocardiac and/or cardiorenal syndrome.

~~8. Method for treating and/or preventing acute and/or chronic kidney disorders with or without concomitant acute and/or chronic heart disease, as a result of renocardiac and/or cardiorenal syndrome in humans and animals, using an effective amount of at least one compound of formula (I), as defined in one of Claims 1 to 7, or of a medicinal product comprising at least one compound of formula (I) as defined in one of Claims 1 to 7 in combination with an inert, nontoxic pharmaceutically suitable additive.~~